Guidelines for diagnosis and treatment of 21-hydroxylase deficiency (2014 revision)
-
- Ishii Tomohiro
- Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan
-
- Anzo Makoto
- Department of Pediatrics, Kawasaki City Hospital, Kanagawa, Japan
-
- Adachi Masanori
- Department of Endocrinology and Metabolism, Kanagawa Children’s Medical Center, Kanagawa, Japan
-
- Onigata Kazumichi
- Shimane University Hospital Postgraduate Clinical Training Center, Shimane, Japan
-
- Kusuda Satoshi
- Maternal and Perinatal Center, Tokyo Women’s Medical University, Tokyo, Japan
-
- Nagasaki Keisuke
- Division of Pediatrics, Department of Homeostatic Regulation and Development, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
-
- Harada Shohei
- Division of Neonatal Screening, National Center for Child Health and Development, Tokyo, Japan
-
- Horikawa Reiko
- Department of Endocrinology and Metabolism, National Center for Child Health and Development, Tokyo, Japan
-
- Minagawa Masanori
- Division of Endocrinology, Chiba Children’s Hospital, Chiba, Japan
-
- Minamitani Kanshi
- Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan
-
- Mizuno Haruo
- Departments of Pediatrics and Neonatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
-
- Yamakami Yuji
- Kanagawa Health Service Association, Kanagawa, Japan
-
- Fukushi Masaru
- Sapporo IDL, Sapporo, Japan
-
- Tajima Toshihiro
- Department of Pediatrics, Department of Pediatrics, Hokkaido University School of Medicine, Sapporo, Japan
この論文をさがす
説明
Purpose of developing the guidelines: The first guidelines for diagnosis and treatment of 21-hydroxylase deficiency (21-OHD) were published as a diagnostic handbook in Japan in 1989, with a focus on patients with severe disease. The “Guidelines for Treatment of Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency) Found in Neonatal Mass Screening (1999 revision)” published in 1999 were revised to include 21-OHD patients with very mild or no clinical symptoms. Accumulation of cases and experience has subsequently improved diagnosis and treatment of the disease. Based on these findings, the Mass Screening Committee of the Japanese Society for Pediatric Endocrinology further revised the guidelines for diagnosis and treatment. Target disease/conditions: 21-hydroxylase deficiency. Users of the guidelines: Physician specialists in pediatric endocrinology, pediatric specialists, referring pediatric practitioners, general physicians; and patients.
収録刊行物
-
- Ｃｌｉｎｉｃａｌ Ｐｅｄｉａｔｒｉｃ Ｅｎｄｏｃｒｉｎｏｌｏｇｙ
-
Ｃｌｉｎｉｃａｌ Ｐｅｄｉａｔｒｉｃ Ｅｎｄｏｃｒｉｎｏｌｏｇｙ 24 (3), 77-105, 2015
日本小児内分泌学会
